Table 3.
Any-grade cancer | Biopsy positive | Biopsy negative | Total | Performance | |
---|---|---|---|---|---|
PCA3 | |||||
≥Cutoff point | 10 | 28 | 38 | PPV % | 26.32 |
<Cutoff point | 4 | 15 | 19 | NPV % | 78.95 |
Total | 14 | 43 | 57 | ||
LBXexo score | |||||
≥Cutoff point | 12 | 17 | 29 | PPV % | 41.38 |
<Cutoff point | 2 | 26 | 28 | NPV % | 92.86 |
Total | 14 | 43 | 57 | ||
Sensitivity % | Specificity % | % of predicted negative | |||
PCA3 | 71.4 | 34.9 | 33.33 | ||
LBXexo | 85.7 | 60.5 | 50.88 | ||
| |||||
High-grade cancer (GS ≥ 7) | Biopsy positive | Biopsy negative + low-grade cancer | Total | Performance | |
| |||||
PCA3 | |||||
≥Cutoff point | 7 | 31 | 38 | PPV % | 18.42 |
<Cutoff point | 1 | 18 | 19 | NPV % | 94.74 |
Total | 8 | 49 | 57 | ||
LBXexo score | |||||
≥Cutoff point | 8 | 21 | 29 | PPV % | 27.59 |
<Cutoff point | 0 | 28 | 28 | NPV % | 100 |
Total | 8 | 49 | 57 | ||
Sensitivity % | Specificity % | % of predicted negative | |||
PCA3 | 87.5 | 36.7 | 33.33 | ||
LBXexo | 100 | 57.1 | 49.12 |
Abbreviations: PPV, positive predictive value; NPV, negative predictive value.